The benefit of real-world evidence is that it provides more data on subpopulations and diverse populations, said Christina Barrington, vice president of pharmacy programs at Priority Health.
The benefit of real-world evidence is that it provides more data on subpopulations and diverse populations, said Christina Barrington, vice president of pharmacy programs at Priority Health.
Transcript
The use of real-world evidence has been seen as a way to rapidly expand indications for existing therapies without the cost of a new phase 3 trial. What are the pros and cons of this approach?
So, I think when you look at it from the perspective of a health plan, the research, the real-world evidence, provides potential future impacts when it comes to clinical decision making, such as formulary, management, utilization, management, tier placement, etc. While we have also noticed with the real-world evidence that there are perceived barriers, you know, with a timeliness experience with the data, sometimes potential for bias, there's also many perceived benefits that we see. So, it gives us increased data about subpopulations, diverse populations, patient-reported outcomes, health care resource utilization costs, and really helps us formulate our coverage strategy based on the additional data.
With real-world evidence, and its potential for future impact, it informs safety monitoring…also helps with formulary and utilization management, and then, you know, really gives us a better idea of how it's really, for lack of better way of saying it, how it's really working in the patient outside of the study design, right? Well, that's a very controlled environment.
Real-world evidence is viewed as a way to capture data from populations that have traditionally been hard to enroll in clinical trials. Is this a valid approach, or should researchers redouble outreach efforts in communities that are underrepresented in trials?
Well, I think that there's still an opportunity that researchers should reach out and secure those subpopulations or diverse populations for trials. But in many trials, if that's not available, or they don't have the opportunity to do that, then I do think that the real-world evidence does give us insight into those subpopulations and diverse populations. As I mentioned previously, I think that is a benefit of real-world evidence.
Contributor: More Informed Management of Preeclampsia Is Necessary
November 29th 2023At present, it is difficult for clinicians to identify patients at greatest risk for developing preeclampsia with severe features and tailor treatment plans for them; this difficulty increases costs significantly.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Provisional CDC data show that US babies gained roughly a year in life expectancy in 2022; study findings indicate that the COVID-19 pandemic significantly raised the risk of preterm birth for expectant California mothers; New York Attorney General Letitia James said about 4 million New Yorkers were affected by a data breach of the medical transcription company Perry Johnson & Associates.
Read More
Nathan Walcker Discusses Value-Based Oncology Care Initiatives at FCS
September 8th 2023Nathan Walcker, CEO at Florida Cancer Specialists & Research Institute (FCS), highlights some of the recent partnerships and initiatives at FCS to improve community-based oncology care from a value-based perspective.
Listen
Gene Therapy Success in UK Likely Depends on Overcoming Education, Psychological Support Challenges
November 27th 2023Education, psychological support, and implementation guidance are the top unmet needs identified by investigators from the United Kingdom concerning gene therapy use for hemophilia.
Read More